coumarin has been researched along with Lung Neoplasms in 15 studies
2H-chromen-2-one: coumarin derivative
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 57-year-old male patient with advanced adenocarcinoma of the lung, who was administered oral anticoagulant therapy because of pulmonary embolism, developed coumarin necrosis confined to the penis and feet." | 8.80 | A case of coumarin necrosis with penile and pedal involvement. ( Baloğlu, H; Başak, M; Doğan, B; Harmanyeri, Y; Taşkapan, O, 1998) |
| "This results demonstrate that compound 8b induces caspase-dependent apoptosis as well as cytoprotective autophagy in lung adenocarcinoma cells, which may provide scientific evidence for developing this furoxan-based NO-releasing coumarin derivative as a potential anti-lung adenocarcinoma therapeutic agents." | 7.88 | A hybrid of coumarin and phenylsulfonylfuroxan induces caspase-dependent apoptosis and cytoprotective autophagy in lung adenocarcinoma cells. ( Chen, Y; Dong, M; Feng, M; Guo, Y; Jiang, S; Kuerban, K; Li, J; Wang, Q; Ye, L, 2018) |
| "Coumarin in vivo has antitumor activity in various types of cancer." | 5.31 | Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. ( Elizalde-Galvan, P; García-Mondragón, MJ; Jiménez-Orozco, FA; León-Cedeño, F; López-González, JS; Mandoki, JJ; Mendoza-Patiño, N; Molina-Guarneros, JA; Nieto-Rodriguez, A; Velasco-Velázquez, MA, 2001) |
| "A 57-year-old male patient with advanced adenocarcinoma of the lung, who was administered oral anticoagulant therapy because of pulmonary embolism, developed coumarin necrosis confined to the penis and feet." | 4.80 | A case of coumarin necrosis with penile and pedal involvement. ( Baloğlu, H; Başak, M; Doğan, B; Harmanyeri, Y; Taşkapan, O, 1998) |
| "This results demonstrate that compound 8b induces caspase-dependent apoptosis as well as cytoprotective autophagy in lung adenocarcinoma cells, which may provide scientific evidence for developing this furoxan-based NO-releasing coumarin derivative as a potential anti-lung adenocarcinoma therapeutic agents." | 3.88 | A hybrid of coumarin and phenylsulfonylfuroxan induces caspase-dependent apoptosis and cytoprotective autophagy in lung adenocarcinoma cells. ( Chen, Y; Dong, M; Feng, M; Guo, Y; Jiang, S; Kuerban, K; Li, J; Wang, Q; Ye, L, 2018) |
| "The study opens up a new strategy to treat lung cancer especially in cases of drug resistance." | 1.38 | Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. ( Anish, C; Bagchi, T; Jinturkar, KA; Kumar, MK; Misra, AR; Panda, AK, 2012) |
| "Coumarin in vivo has antitumor activity in various types of cancer." | 1.31 | Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. ( Elizalde-Galvan, P; García-Mondragón, MJ; Jiménez-Orozco, FA; León-Cedeño, F; López-González, JS; Mandoki, JJ; Mendoza-Patiño, N; Molina-Guarneros, JA; Nieto-Rodriguez, A; Velasco-Velázquez, MA, 2001) |
| "Coumarin was also shown to possess antimetastatic activity in a Dunning R3327-MatLu tumour model." | 1.29 | Antitumour activity of coumarin in prostate and mammary cancer models. ( Kager, M; Maucher, A; von Angerer, E, 1994) |
| "Coumarin was also shown to possess antimetastatic activity in a Dunning R3327-MatLu tumour model." | 1.29 | Evaluation of the antitumour activity of coumarin in prostate cancer models. ( Kager, M; Maucher, A; von Angerer, E, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| Guo, Y | 1 |
| Jiang, S | 1 |
| Dong, M | 1 |
| Kuerban, K | 1 |
| Li, J | 1 |
| Feng, M | 1 |
| Chen, Y | 1 |
| Ye, L | 1 |
| Kim, YH | 1 |
| Shin, EA | 1 |
| Jung, JH | 1 |
| Park, JE | 1 |
| Koo, J | 1 |
| Koo, JI | 1 |
| Shim, BS | 1 |
| Kim, SH | 1 |
| Riaz, MK | 1 |
| Zhang, X | 1 |
| Wong, KH | 1 |
| Chen, H | 1 |
| Liu, Q | 1 |
| Chen, X | 1 |
| Zhang, G | 1 |
| Lu, A | 1 |
| Yang, Z | 1 |
| Cruzan, G | 1 |
| Bus, J | 1 |
| Banton, M | 1 |
| Gingell, R | 1 |
| Carlson, G | 1 |
| Jinturkar, KA | 1 |
| Anish, C | 1 |
| Kumar, MK | 1 |
| Bagchi, T | 1 |
| Panda, AK | 1 |
| Misra, AR | 1 |
| Musa, MA | 1 |
| Badisa, VL | 1 |
| Latinwo, LM | 1 |
| Patterson, TA | 1 |
| Owens, MA | 1 |
| Lopez-Gonzalez, JS | 2 |
| Prado-Garcia, H | 1 |
| Aguilar-Cazares, D | 1 |
| Molina-Guarneros, JA | 2 |
| Morales-Fuentes, J | 1 |
| Mandoki, JJ | 2 |
| Miyazaki, M | 1 |
| Yamazaki, H | 1 |
| Takeuchi, H | 1 |
| Saoo, K | 1 |
| Yokohira, M | 1 |
| Masumura, K | 1 |
| Nohmi, T | 1 |
| Funae, Y | 1 |
| Imaida, K | 1 |
| Kamataki, T | 1 |
| Elinos-Báez, CM | 1 |
| León, F | 1 |
| Santos, E | 1 |
| von Angerer, E | 2 |
| Kager, M | 2 |
| Maucher, A | 2 |
| Harmanyeri, Y | 1 |
| Taşkapan, O | 1 |
| Doğan, B | 1 |
| Baloğlu, H | 1 |
| Başak, M | 1 |
| Jiménez-Orozco, FA | 1 |
| Nieto-Rodriguez, A | 1 |
| Velasco-Velázquez, MA | 1 |
| Mendoza-Patiño, N | 1 |
| García-Mondragón, MJ | 1 |
| Elizalde-Galvan, P | 1 |
| León-Cedeño, F | 1 |
| Herrmann, R | 1 |
| Manegold, C | 1 |
| Maurer, B | 1 |
| Hennig, FW | 1 |
| Matthiessen, W | 1 |
| Marshall, ME | 1 |
| Mendelsohn, L | 1 |
| Butler, K | 1 |
| Cantrell, J | 1 |
| Harvey, J | 1 |
| Macdonald, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of 4-Methylumbelliferone for Treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV)[NCT00225537] | Phase 2 | 160 participants | Interventional | 2005-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for coumarin and Lung Neoplasms
| Article | Year |
|---|---|
Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: an endpoint/toxic response where data from multiple chemicals converge to support a mode of action.
Topics: Adenocarcinoma; Adenoma; Animals; Bronchioles; Carcinogens; Cell Proliferation; Coumarins; Cytochrom | 2009 |
A case of coumarin necrosis with penile and pedal involvement.
Topics: Adenocarcinoma; Anticoagulants; Coumarins; Foot Dermatoses; Humans; Lung Neoplasms; Male; Middle Age | 1998 |
1 trial available for coumarin and Lung Neoplasms
| Article | Year |
|---|---|
Phase II trial of coumarin and cimetidine in advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 1990 |
12 other studies available for coumarin and Lung Neoplasms
| Article | Year |
|---|---|
A hybrid of coumarin and phenylsulfonylfuroxan induces caspase-dependent apoptosis and cytoprotective autophagy in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Autophagy; Aut | 2018 |
Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Caspase 8; | 2019 |
Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Coumarins; Disease Models, Animal | 2019 |
Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines.
Topics: Annexin A5; beta-Galactosidase; Cell Death; Cell Line, Tumor; Chemistry, Pharmaceutical; Coumarins; | 2012 |
Coumarin-based benzopyranone derivatives induced apoptosis in human lung (A549) cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Coumarins; Down-Regu | 2012 |
Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcin | 2004 |
Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.
Topics: Adenoma; Animals; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Carcinogens; Chemoprevention | 2005 |
Effects of coumarin and 7OH-coumarin on bcl-2 and Bax expression in two human lung cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squ | 2005 |
Antitumour activity of coumarin in prostate and mammary cancer models.
Topics: Adenocarcinoma; Animals; Coumarins; Disease Models, Animal; Female; Lung Neoplasms; Male; Mammary Ne | 1994 |
Evaluation of the antitumour activity of coumarin in prostate cancer models.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Administration Schedule; Drug Screening Assays, Anti | 1993 |
Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin.
Topics: Adenocarcinoma; Antineoplastic Agents; Biotransformation; Cell Cycle; Cell Division; Coumarins; Cycl | 2001 |
Treatment of non-small cell lung cancer with coumarin and cimetidine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cimetid | 1987 |